Non-acral cutaneous type (low- and high-CSD types) treated with anti-PD-1 Abs or dabrafenib plus trametinib combined therapy showed a significantly better TTR compared to acral melanoma (HR, 0.56; 95% CI: 0.34–0.92; p = 0.021, Figure 1a). The gene discussed is PDCD1; the disease is acral lentiginous melanoma.